Rapport Therapeutics, Inc. (RAPP)
| Market Cap | 1.84B +491.3% |
| Revenue (ttm) | 20.00M |
| Net Income | -107.28M |
| EPS | -2.56 |
| Shares Out | 47.83M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 255,556 |
| Open | 35.62 |
| Previous Close | 35.21 |
| Day's Range | 35.61 - 39.17 |
| 52-Week Range | 10.51 - 42.27 |
| Beta | 0.98 |
| Analysts | Strong Buy |
| Price Target | 57.10 (+48.7%) |
| Earnings Date | May 7, 2026 |
About RAPP
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company’s lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorde... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for RAPP stock is "Strong Buy." The 12-month stock price target is $57.1, which is an increase of 48.70% from the latest price.
News
Rapport Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum and proceeded with the election of three directors and the ratification of the audit firm, both of which were approved by stockholders. No additional nominations or questions were received, and all proposals passed as recommended.
Rapport Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Phase III trials for RAP-219 in focal-onset seizures are enrolling globally, supported by strong phase II data and a China partnership to accelerate recruitment. The pipeline includes upcoming trials in bipolar mania, primary generalized tonic-clonic seizures, and pain, with a cash runway into 2029.
Rapport Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
RAP-219, a precision neuroscience asset, is advancing through phase III trials for focal epilepsy, with strong phase II efficacy and a robust safety focus. A long-acting injectable is in development, and pivotal data for bipolar mania and open label extension are expected in Q4.
Rapport Therapeutics price target raised to $65 from $53 at BTIG
BTIG raised the firm’s price target on Rapport Therapeutics (RAPP) to $65 from $53 and keeps a Buy rating on the shares. The firm is citing clinical execution behind its…
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
BOSTON and SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and dev...
Rapport Therapeutics assumed with a Buy at Truist
Truist assumed coverage of Rapport Therapeutics (RAPP) with a Buy rating with a price target of $56, up from $44. The firm’s thesis is largely consistent with its most recently…
Rapport Therapeutics reports Q1 EPS (42c), consensus (71c)
Reports Q1 revenue $20,000, consensus $6M. “We entered 2026 with strong momentum across the RAP-219 development program, highlighted by compelling new follow-up Phase 2a data recently presented at AAN...
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12 RA...
Rapport Therapeutics Earnings release: Q1 2026
Rapport Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Rapport Therapeutics Quarterly report: Q1 2026
Rapport Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Rapport Therapeutics Slides: Corporate presentation
Rapport Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Modalités de mise à disposition du rapport financier annuel 2025
MODALITES DE MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 La société AdVini annonce avoir mis à la disposition du public et déposé auprès de l'Autorité des Marchés Financiers son Rapport Financ...
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025
MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025 Dijon, France le 30 avril 2026 (17h45 CET) -- CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), société pharmaceutique spécialisée en phase avancée de...
Rapport Therapeutics Proxy statement: Proxy filing
Rapport Therapeutics filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Rapport Therapeutics Proxy statement: Proxy filing
Rapport Therapeutics filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Rapport Therapeutics presents results from Phase 2a trial of RAP-219
Rapport Therapeutics (RAPP) announced results from the follow-up period of its Phase 2a trial of RAP-219 in focal onset seizures, FOS, in a late-breaker podium presentation at the 2026 American…
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in clin...
Rapport Therapeutics Slides: Corporate presentation
Rapport Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on April 21, 2026.
Rapport Therapeutics initiated with a Strong Buy at Raymond James
Raymond James analyst Tiago Fauth last night initiated coverage of Rapport Therapeutics (RAPP) with a Strong Buy rating and $66 price target The firm believes investors are not paying attention…
Rapport Therapeutics initiated with a Strong Buy at Raymond James
Raymond James initiated coverage of Rapport Therapeutics (RAPP) with a Strong Buy rating and $66 price target
Rapport Therapeutics initiated with a Strong Buy at Raymond James
Raymond James initiated coverage of Rapport Therapeutics (RAPP) with a Strong Buy rating and $66 price target
Communiqué de mise à disposition du rapport financier annuel 2025
A Paris, le 8 avril 2026 COMMUNIQUE INFORMATION REGLEMENTEE Communiqué précisant les modalités de mise à disposition du Rapport financier annuel 2025 de Crédit Mutuel Home Loan SFH Crédit Mutuel Home ...
Neuphonic and Rapport Bring Real-Time Digital Humans to Everyday Hardware
LONDON--(BUSINESS WIRE)--Neuphonic and Rapport (a division of Speech Graphics) today announced a partnership to deliver what they believe is among the first fully real-time, photorealistic digital hum...
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and d...
CRCAM Toulouse 31 - Rapport financier annuel 2025
Ci-joint le rapport financier annuel 2025 Attachment Rapport Financier CRCAM 2025